CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancerRaymond J. Lim, Bin Liu, Jensen Abascal et al.|Cell Reports Medicine|2024Cited by 111
Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non–Small Cell Lung CancerRui Li, Steven M. Dubinett, Kostyantyn Krysan et al.|Cancer Research|2021Cited by 98
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunityRamin Salehi‐Rad, Steven M. Dubinett, Jensen Abascal et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 30
Abstract 4208: <i>In situ</i> vaccination of non-small cell lung cancer with CXCL9/10-engineered dendritic cells combined with PD-1 blockadeRaymond J. Lim, Steven M. Dubinett, Jensen Abascal et al.|Cancer Research|2022Cited by 1